uMSC and ACE2-uMSC treatments resulted in reduced expression of TIMP-1 (P<0.05) and TIMP-4 (P<0.05 and P<0.01, respectively) compared with that of the BLM group. The gene discussed is TIMP1; the disease is Bloom syndrome.